Skip to main content
PMC home page
Archives of Disease in Childhood. Fetal and Neonatal Edition logoLink to Archives of Disease in Childhood. Fetal and Neonatal Edition
. 2004 Sep;89(5):F456–F460. doi: 10.1136/adc.2002.009837

Natural history of hepatitis B in perinatally infected carriers

E Boxall, J Sira, R Standish, P Davies, E Sleight, A Dhillon, P Scheuer, D Kelly
PMCID: PMC1721758  PMID: 15321970

Abstract

Objectives: To establish natural seroconversion rates and incidence of hepatic pathology in perinatally infected hepatitis B carriers.

Methods: Seventy three perinatally infected hepatitis B carriers identified through maternal screening were evaluated. Fifty three were born to parents from the Indian subcontinent, nine were Oriental, six were Afro-Caribbean, and five were white. Median follow up was 10.24 (range 2.02–20.16) years.

Results: Only three of the children followed up had cleared hepatitis B surface antigen during this period, and 30% of the children had seroconverted to anti-HBe. Seroconversions to anti-HBe were observed in Asian (18/50) and white (4/5) children, but not in Oriental or Afro-Caribbean children. More girls (40%) than boys (23%) had seroconverted, but the difference was not significant. All children were asymptomatic with normal physical examination, growth, and development. Almost half (48%) of the hepatitis B e antigen (HBeAg) positive children had normal hepatic transaminases and liver function. Thirty five liver biopsies were performed in children with active virus replication (HBeAg or hepatitis B virus DNA positive) who were being considered for antiviral treatment as part of a clinical trial and were scored using the Ishak method. Two thirds (62%) of the children had mild hepatitis, 60% had mild fibrosis, and 18% had moderate to severe fibrosis. There was a weak correlation between histological evidence of hepatitis and hepatic transaminase activity, implying that biochemical monitoring of hepatic disease activity may be ineffective.

Conclusions: These asymptomatic hepatitis B virus carrier children remain infectious in the medium to long term with notable liver pathology. They should receive antiviral treatment to reduce infectivity and to prevent further progression of liver disease. Hepatic transaminases alone are not a reliable marker of liver pathology, and liver histology is essential before consideration for antiviral treatment.

Full Text

The Full Text of this article is available as a PDF (62.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arthur M. J., Hall A. J., Wright R. Hepatitis B, hepatocellular carcinoma, and strategies for prevention. Lancet. 1984 Mar 17;1(8377):607–610. doi: 10.1016/s0140-6736(84)91006-7. [DOI] [PubMed] [Google Scholar]
  2. Ballard A. L., Boxall E. H. Assessing the infectivity of hepatitis B carriers. Commun Dis Public Health. 1999 Sep;2(3):178–183. [PubMed] [Google Scholar]
  3. Beasley R. P., Hwang L. Y., Lin C. C., Chien C. S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981 Nov 21;2(8256):1129–1133. doi: 10.1016/s0140-6736(81)90585-7. [DOI] [PubMed] [Google Scholar]
  4. Bortolotti F., Cadrobbi P., Crivellaro C., Guido M., Rugge M., Noventa F., Calzia R., Realdi G. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology. 1990 Sep;99(3):805–810. doi: 10.1016/0016-5085(90)90972-4. [DOI] [PubMed] [Google Scholar]
  5. Bortolotti F., Calzia R., Cadrobbi P., Giacchini R., Ciravegna B., Armigliato M., Piscopo R., Realdi G. Liver cirrhosis associated with chronic hepatitis B virus infection in childhood. J Pediatr. 1986 Feb;108(2):224–227. doi: 10.1016/s0022-3476(86)80987-8. [DOI] [PubMed] [Google Scholar]
  6. Bortolotti F., Jara P., Crivellaro C., Hierro L., Cadrobbi P., Frauca E., Camarena C., De La Vega A., Diaz C., De Moliner L. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol. 1998 Aug;29(2):184–190. doi: 10.1016/s0168-8278(98)80002-0. [DOI] [PubMed] [Google Scholar]
  7. Bruno S., Rossi S., Petroni M. L., Villa E., Zuin M., Podda M. Normal aminotransferase concentrations in patients with antibodies to hepatitis C virus. BMJ. 1994 Mar 12;308(6930):697–697. doi: 10.1136/bmj.308.6930.697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chan C. Y., Lee S. D., Yu M. I., Wang Y. J., Tsai Y. T., Lo K. J. Long-term follow-up of hepatitis B virus carrier infants. J Med Virol. 1994 Dec;44(4):336–339. doi: 10.1002/jmv.1890440405. [DOI] [PubMed] [Google Scholar]
  9. Chang M. H., Sung J. L., Lee C. Y., Chen C. J., Chen J. S., Hsu H. Y., Lee P. I., Chen D. S. Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children. J Pediatr. 1989 Sep;115(3):385–390. doi: 10.1016/s0022-3476(89)80836-4. [DOI] [PubMed] [Google Scholar]
  10. Chu C. M. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2000 May;15 (Suppl):E25–E30. doi: 10.1046/j.1440-1746.2000.02097.x. [DOI] [PubMed] [Google Scholar]
  11. Derso A., Boxall E. H., Tarlow M. J., Flewett T. H. Transmission of HBsAg from mother to infant in four ethnic groups. Br Med J. 1978 Apr 15;1(6118):949–952. doi: 10.1136/bmj.1.6118.949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Evans A. A., Fine M., London W. T. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy. J Infect Dis. 1997 Oct;176(4):845–850. doi: 10.1086/516538. [DOI] [PubMed] [Google Scholar]
  13. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., Denk H., Desmet V., Korb G., MacSween R. N. Histological grading and staging of chronic hepatitis. J Hepatol. 1995 Jun;22(6):696–699. doi: 10.1016/0168-8278(95)80226-6. [DOI] [PubMed] [Google Scholar]
  14. Karayiannis P., Novick D. M., Lok A. S., Fowler M. J., Monjardino J., Thomas H. C. Hepatitis B virus DNA in saliva, urine, and seminal fluid of carriers of hepatitis B e antigen. Br Med J (Clin Res Ed) 1985 Jun 22;290(6485):1853–1855. doi: 10.1136/bmj.290.6485.1853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lok A. S., Lai C. L. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology. 1988 Sep-Oct;8(5):1130–1133. doi: 10.1002/hep.1840080527. [DOI] [PubMed] [Google Scholar]
  16. Lok A. S., Lai C. L., Chung H. T., Lau J. Y., Leung E. K., Wong L. S. Morbidity and mortality from chronic hepatitis B virus infection in family members of patients with malignant and nonmalignant hepatitis B virus-related chronic liver diseases. Hepatology. 1991 May;13(5):834–837. doi: 10.1002/hep.1840130506. [DOI] [PubMed] [Google Scholar]
  17. Viola L. A., Barrison I. G., Coleman J. C., Paradinas F. J., Fluker J. L., Evans B. A., Murray-Lyon I. M. Natural history of liver disease in chronic hepatitis B surface antigen carriers. Survey of 100 patients from Great Britain. Lancet. 1981 Nov 21;2(8256):1156–1159. doi: 10.1016/s0140-6736(81)90600-0. [DOI] [PubMed] [Google Scholar]
  18. Wallis D. E., Boxall E. H. Immunisation of infants at risk of perinatal transmission of hepatitis B: retrospective audit of vaccine uptake. BMJ. 1999 Apr 24;318(7191):1112–1113. doi: 10.1136/bmj.318.7191.1112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wheeley S. M., Boxall E. H., Tarlow M. J., Gatrad A. R., Anderson J., Bissenden J., Chin K. C., Mayne A. Hepatitis B vaccine in the prevention of perinatally transmitted hepatitis B virus infection: final report on a West Midlands pilot study. J Med Virol. 1990 Feb;30(2):113–116. doi: 10.1002/jmv.1890300207. [DOI] [PubMed] [Google Scholar]
  20. Wheeley S. M., Boxall E. H., Tarlow M. J. Prognosis of children who are carriers of hepatitis B. Br Med J (Clin Res Ed) 1987 Jan 24;294(6566):211–213. doi: 10.1136/bmj.294.6566.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Wheeley S. M., Jackson P. T., Boxall E. H., Tarlow M. J., Gatrad A. R., Anderson J., Bissenden J. Prevention of perinatal transmission of hepatitis B virus (HBV): a comparison of two prophylactic schedules. J Med Virol. 1991 Nov;35(3):212–215. doi: 10.1002/jmv.1890350312. [DOI] [PubMed] [Google Scholar]
  22. Wheeley S. M., Tarlow M. J., Boxall E. H. Chronic hepatitis B in male and female children of HBsAg carrier mothers. J Hepatol. 1989 Mar;8(2):226–231. doi: 10.1016/0168-8278(89)90011-1. [DOI] [PubMed] [Google Scholar]
  23. Wong D. K., Cheung A. M., O'Rourke K., Naylor C. D., Detsky A. S., Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993 Aug 15;119(4):312–323. doi: 10.7326/0003-4819-119-4-199308150-00011. [DOI] [PubMed] [Google Scholar]
  24. Yuen M. F., Lai C. L. Natural history of chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2000 May;15 (Suppl):E20–E24. doi: 10.1046/j.1440-1746.2000.02123.x. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood Fetal and Neonatal Edition are provided here courtesy of BMJ Publishing Group

RESOURCES